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IT-101, a cyclodextrin polymer-based nanoparticle containing
camptothecin, is in clinical development for the treatment of
cancer. Multiorgan pharmacokinetics and accumulation in tumor
tissue of IT-101 is investigated by using PET. IT-101 is modified
through the attachment of a 1,4,7,10-tetraazacyclododecane-1,4,7-
Tris-acetic acid ligand to bind 64Cu2. This modification does not
affect the particle size and minimally affects the surface charge of
the resulting nanoparticles. PET data from 64Cu-labeled IT-101 are
used to quantify the in vivo biodistribution in mice bearing
Neuro2A s.c. tumors. The 64Cu-labeled IT-101 displays a biphasic
plasma elimination. Approximately 8% of the injected dose is
rapidly cleared as a low-molecular-weight fraction through the
kidneys. The remaining material circulates in plasma with a termi-
nal half-life of 13.3 h. Steadily increasing concentrations, up to 11%
injected dose per cm3, are observed in the tumor over 24 h, higher
than any other tissue at that time. A 3-compartment model is used
to determine vascular permeability and nanoparticle retention in
tumors, and is able to accurately represent the experimental data.
The calculated tumor vascular permeability indicates that the
majority of nanoparticles stay intact in circulation and do not
disassemble into individual polymer strands. A key assumption to
modeling the tumor dynamics is that there is a ‘‘sink’’ for the
nanoparticles within the tumor. Histological measurements using
confocal microscopy show that IT-101 localizes within tumor cells
and provides the sink in the tumor for the nanoparticles.
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Chemotherapeutics are the mainstay of cancer treatment foradvanced and/or metastatic tumors. However, their effec-
tiveness is typically limited by toxicity in healthy, normal tissues
with rapidly dividing cells, such as bone marrow or the gastro-
intestinal tract. One approach to increase the therapeutic index
of chemotherapeutics is site-directed delivery by using various
carrier systems. Numerous types of delivery technologies have
been developed for this purpose, such as liposomes (1, 2),
conjugates with antibodies or small molecules targeted to tumor
antigens (3, 4), and macromolecular polymer carriers (5). Car-
rier-drug composites are nanoscaled therapeutics, and nanopar-
ticle cancer therapeutics that have been used in humans have
been reviewed elsewhere (6).
The use of nanoscaled therapeutics takes advantage of the
unique tumor physiology characterized by a high density of
abnormal blood vessels, high vascular permeability, and de-
creased rate of clearance due to a lack of lymphatic drainage, all
of which act together to cause accumulation of macromolecules
through the enhanced permeability and retention (EPR) effect
(7). The magnitude of this effect is affected by a number of
parameters that are either host-related (tumor perfusion, vas-
cularity, vascular permeability) or nanoparticle-related (plasma
half-life, clearance, hydrodynamic size, surface charge). For
example, the hydrodynamic size of macromolecules (or molec-
ular weight, which is directly correlated to hydrodynamic size)
appears to be the dominant factor strongly influencing both
plasma half-life and vascular permeability. For macromolecules
and nanoparticles of 100 nm, plasma half-life is directly
correlated, whereas extravasation is inversely correlated, with
hydrodynamic diameter (8–12). Surface charge has some effect;
e.g., highly cationic polymers show increased clearance com-
pared with those that are negatively or neutrally charged (13).
Interestingly, the incorporation of targeting ligands appears to
have a minor effect on the biodistribution of nanoparticles to
tumors, but may rather affect cellular interactions and therefore
improve efficacy for drugs that require intracellular delivery (14,
15). In addition to the EPR effect, nanoscaled carriers improve
the pharmacokinetics and pharmacodynamics of small molecule
chemotherapeutics through a variety of other mechanisms such
as: (i) enhancing their solubility and therefore reducing third-
spacing, (ii) protecting drugs from enzymatic or hydrolytic
degradation, (iii) controlling release-kinetics to more closely
match the mode of action of these drugs, and (iv) overcoming
multidrug resistance by intracellular delivery through endocy-
tosis rather than diffusion, a process that is less susceptible to
surface-pump-mediated multidrug resistance.
Linear, cyclodextrin-based polymers (CDPs) are a unique
carrier system for chemotherapeutics and other small molecule
drugs (for reviews see refs.16 and 17) because they incorporate
-cyclodextrin, a cyclical sugar with the ability to form inclu-
sion complexes with hydrophobic moieties within the center of
its cup-like structure, into a highly water soluble, neutrally
charged backbone containing PEG. When small molecule
drugs are covalently attached to this polymer through various
cleavable linkers, the resulting macromolecular prodrugs self-
assemble into nanoparticles with a hydrodynamic diameter of
100 nm. Several conjugates with highly potent small mole-
cule antineoplastic agents have been synthesized and demon-
strated enhanced solubility, improved plasma pharmacokinet-
ics, improved tolerability, and increased potency compared
with the small molecule analogs (18–22). One nanoparticle
that is comprised of a CDP conjugate of the small molecule
drug camptothecin (CPT) is named IT-101 (18–21), and is in
clinical development (23).
Here, we investigate the transport phenomena of IT-101 (a
nanoparticle measuring 30–40 nm in diameter) by using PET.
This technology allows the simultaneous and noninvasive mea-
surement of whole-body, multiple-organ pharmacokinetics, in-
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cluding the distribution to tumors, by using a 64Cu-labeled
polymer in tumor-bearing mice. A mathematical model of the
nanoparticle behavior is presented and is shown to accurately
describe the behavior of IT-101. A key assumption in the model
is that there is a ‘‘sink’’ within the tumor for the nanoparticles.
Histological sections from tumors evaluated by confocal micros-
copy show that IT-101 resides within tumor cells and this
localization is the sink for the nanoparticles.
Results
Synthesis of 64Cu-Labeled Polymer Conjugate. 1,4,7,10-tetraazacy-
clododecane-1,4,7-Tris-acetic acid (DOTA) was grafted onto a
CDP conjugate of CPT at a molar ratio of 3 CPT to 1 DOTA (SI
Appendix, Fig. S1). In the resulting conjugate, the DOTA is
attached to the polymer through a maleimide linker. The
structure of the DOTA-containing polymer conjugate is very
similar to that in IT-101. After Cu loading, the resulting polymer
conjugate self-assembled into nanoparticles with a similar par-
ticle size as IT-101 (37 nm vs. 36 nm, SI Appendix, Table S1) and
a minor increase in negative surface charge (9.4 mV vs. 1.8
mV, SI Appendix, Table S1). The change in the surface charge
can be attributed to the presence of 1 excess carboxylic acid
group per DOTA molecule. Cu binding was found to be exclu-
sively through the DOTA groups because no Cu was detected in
IT-101 loaded with Cu in the same way (SI Appendix, Table S1).
Plasma Pharmacokinetics. MicroPET/CT was used to determine
the plasma pharmacokinetics of 64Cu-labeled nanoparticles
after i.v. injection in tumor-bearing mice. MicroPET images at
4 h and 24 h after injection are shown in Fig. 1A. The PET
signal in various organs was measured and the percent of
injected dose (ID) per cm3 for each region of interest was
calculated for each time-point. Data for the first 60 min
averaged over 6 animals evaluated in 2 independent experi-
ments are provided in the SI Appendix, Fig. S2. Plasma and
tumor curves expanded to 24 h are shown in Fig. 2B. To
calculate blood concentration, an area of interest was drawn
around the mediastenum. Plasma concentrations were calcu-
lated by using a mouse whole-body hematocrit of 33% (24).
Plasma showed a biphasic elimination of PET signal with
4.26% ID/mL cleared with a half-life of 10.6 min whereas 19.9%
ID/mL was cleared with a longer half-life of 13.3 h. The
calculated volume of the central plasma compartment was 4.1
mL, 2.7 times the mouse plasma volume.
Biodistribution and Renal Clearance. Coinciding with the initial
plasma clearance phase was a rapid increase in the PET signal
in the renal pelvis, which contains the urine collecting ducts. The
renal pelvis signal peaked at 7.5 min after injection, declining
to less than plasma levels at 20 min after administration (SI
Appendix, Fig. S2). The rapidly clearing fraction of the PET
signal accumulated in the bladder as indicated by a rapid
bladder-signal rise over the first 20 min, followed by a more
gradual increase during the remainder of the first 60 min, to a
total signal of 80% ID/mL (SI Appendix, Fig. S2). Over the first
hour, 8% of injected dose accumulated in the bladder.
Liver and renal cortex PET signals were approximately equal
to blood levels over the first 60 min, declining with the same
half-life. This seems consistent with the high vascularization of
these organs (25, 26), and together with the bladder data seems
to indicate that initial and rapid clearance of a small fraction of
PET label is mostly through the kidney.
To determine whether nanoparticle formulations contained
any low-molecular-weight polymers not incorporated into nano-
particles, we performed membrane fractionation studies (SI
Appendix, Table S2). No significant fraction of membrane-
filterable polymer conjugate was seen below a 100 kDa molec-
ular weight cut-off (MWCO) for a polymer conjugate with an
average MW of 67 kDa, whereas a parent polymer with the same
MW showed a significant filterable fraction in accordance with
its molecular weight. These data indicate that polymer strands
are fully incorporated into nanoparticles with no free, low-
molecular-weight conjugate present in solution. The nanopar-
ticles were expected to avoid first-pass kidney clearance, because
the kidney has a reported MWCO of 48 kDa for other
polymers such as PEG and dextran (27). However, it is possible
that nanoparticle disruption may occur in the blood stream and
release of low-molecular-weight conjugates may contribute to
the rapidly cleared fraction. Because the imaging technology
used here cannot distinguish between intact nanoparticles, in-
dividual polymer conjugate strands or 64Cu labels released from
the polymer, it remains unknown what form of low-molecular-
weight 64Cu is present in the urine.
Signals from the liver (SI Appendix, Fig. S2) show that,
although concentrations are similar to the levels observed in
blood, no accumulation occurs over time. This lack of accu-
mulation may indicate that nanoparticles extravasate from
liver sinusoids into the Disse space but are not taken up to a
significant degree by resident macrophages or hepatocytes.
Extravasation in the liver seems plausible because the fenes-
trations in liver sinusoids have a diameter of 100 nm in the
mouse (28). The liver may therefore function as a depot of
nanoparticles that can exchange back into circulation. Alter-
natively, liver clearance of nanoparticles could have identical
kinetics to plasma clearance. This result also confirms that
there is no significant level of free 64Cu in our nanoparticle
preparation, because free 64Cu has been shown to accumulate
in the liver over 60 min (15). Biodistribution to other organs
such as muscle and brain was low throughout the observation
period, confirming that the nanoparticles show low extrava-
sation into normal tissues (except liver) and do not cross the
intact blood–brain barrier (19).
Fig. 1. Results from PET studies. (A) Fused PET/CT image of a tumor-bearing mouse 4 h (Left) and 24 h (Right) after injection. (B) Tissue distribution at 1, 4, and
24 h after injection. Error bars indicate SEM.
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Tumor Accumulation. In contrast to other tissues that exhibit
concentration-time curves that declined in parallel with plasma
concentration, tumor concentration increased over time, actu-
ally crossing above the plasma concentration level at 24 h after
injection (Figs. 1B and 2B). In fact, at 24 h after injection, the
PET signal was higher in tumor than in any other tissue,
increasing from 4.6 0.7% ID/cm3 at 1 h to 11.0 1.1%ID/cm3
at 24 h after injection (Fig. 1B).
Compartmental Modeling. Tumor concentration was modeled by
using a 3-compartment model (Fig. 2). The initial rapid increase
in total tumor concentration is due to the contribution of the
tumor vasculature to the total signal. Because plasma and
bladder pharmacokinetics indicated the presence of both low-
molecular-weight and nanoparticulate 64Cu species, extravasa-
tion from tumor vasculature was modeled separately for both.
The presence of a low-molecular-weight species of 64Cu leads to
a rapid rise of concentration in the tumor interstitial space (CI,
lmw) that is subsequently cleared with a half-life similar to its
plasma half-life (Fig. 2B). The apparent permeability for this
rapidly clearing 64Cu species was 5.56 105 cm/s. This apparent
permeability is large when compared with the apparent tumor
permeability determined by Dreher et al. (11) for a fluorescently
labeled dextran with 3.3 kDa molecular weight (1.54  105),
indicating that it had a molecular weight significantly below 3
kDa. This result is also consistent with the rapid kidney clearance
observed in our study, because a copper species 3 kDa is
expected to be freely filterable by the kidney.
Tumor interstitial concentration of nanoparticles (CI,NP) in-
creased much more slowly, driven by a significantly smaller
apparent permeability of 3.1  107 cm/s. This permeability is
consistent with nanoparticles of a 37-nm hydrodynamic diameter
but much smaller than what would be expected for a polymer
with a molecular weight of 67 kDa (11) (Fig. 2C). These results
are consistent with the premise that cyclodextrin-based polymer
nanoparticles stay intact in circulation for extended periods of
time and do not disintegrate into individual polymer strands.
Tumor interstitial concentration approaches the plasma concen-
tration by 4 h after injection and decreases subsequently in
parallel with plasma kinetics. The fact that tumor concentration
of label increases above the plasma concentration at some time
between 4 and 24 h suggests that there is a sink for the
nanoparticles within the tumor; e.g., they become trapped in the
tumor tissue or are taken up by cells.
Neuro2A tumors were collected frommice 24 h after injection
of IT-101. Sections were visualized by using confocal microscopy
because CPT emits at 440 nm (SI Appendix, Fig. S3). To prove
that the CPT emission was from IT-101 rather than released
CPT, we developed a stain for IT-101 (see SI Appendix for details
of the stain and control experiments proving that it does stain
IT-101 in cells). The stain is a gold particle that is capped with
thiolated PEG molecules. A portion of these PEG molecules
have adamantane (AD) at the end distal to the thiol. Thus, the
PEGylated gold particles have numerous AD molecules to
provide multivalent binding to the cyclodextrins on the CDP [the
AD–CD interactions have been exploited by us previously
(15–17)]. Thus, the Au-PEG-AD selectively stains IT-101 (SI
Appendix). The capped gold particles emit at 507 nm (SI Ap-
pendix, Fig. S3).
Here, colocalization of CPT and the Au-PEG-AD are used as
evidence for IT-101 as opposed to CPT alone. Fig. 3 shows a
section of a Neuro2A tumor collected 24 h after injection of
IT-101. Note that there is significant colocalization of the
Fig. 2. Modeling of tumor uptake of 64Cu-labeled IT-101 using a 3-compartment model incorporating low molecular weight and nanoparticulate label. (A)
Schematic diagram and governing equations describing the model. (B) Model fit for plasma and tumor concentrations including concentrations in the tumor
interstitial space. (C) Apparent permeability for IT-101 (denoted 64Cu NP) compared with dextran of varying molecular weight. Dextran was replotted based on
data by Dreher et al. (11). See SI Appendix, Table S3 for definition of terms and values used in the simulations.
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emissions from the CPT and the Au-PEG-AD, suggesting that
numerous cancer cells within the tumor have internalized IT-101.
Discussion
In this study we used PET to determine multiorgan pharmaco-
kinetics and biodistribution of a nanoparticle containing the
chemotherapeutic camptothecin in tumor-bearing mice. Essen-
tially, real-time whole-body data for the first 60 min and addi-
tional, discontinuous data up to 24 h after administration were
obtained. These data provide for the observation of fast dynam-
ics and give insights into the behavior of the polymeric nano-
particle system that are not possible from other methodologies.
The PET dynamics complement PK and biodistribution data
acquired at larger time intervals by traditional means.
Self-assembly of multiple polymer chains via inter-strand
CD–CPT inclusion complex formation (each polymer strand is
a multivalent polymer strand) to create nanoparticles is a unique
feature of the cyclodextrin polymer conjugates. The assembly is
not limited to CPT (IT-101) as other conjugated molecules also
allow for nanoparticle formation (22).
Modification of the CDP–CPT conjugate with DOTA resulted
in a structure similar to IT-101, which is currently in clinical trials
for the treatment of cancer. After loading with 64Cu, the
conjugate assembled into nanoparticles with a particle size of 37
nm and slightly negative surface charge similar to what is
observed from IT-101. Plasma pharmacokinetics displayed a
biphasic elimination profile with a low-molecular-weight frac-
tion cleared rapidly through the kidneys and the remaining
nanoparticles circulating with a terminal half-life of 13 h.
These results are consistent with previous IT-101 data in rats
where the terminal half-life was 18 h (19). The nature of the
rapidly clearing low-molecular-weight species could not be de-
termined. However, it is unlikely to be due to the presence of free
copper, because none was detected in the starting materials, and
injected free copper was shown to accumulate in the liver, rather
than being excreted in the urine (15). Possible other explanations
include the release of low-molecular-weight polymer conjugates
from the nanoparticles after i.v. injection or cleavage of the
DOTA ligand from the complex. Copper-loaded DOTA has
previously been shown to be renally cleared (15). Cleavage of
alkyl-maleimide linkers, as used here, has been reported in
plasma, however, the half-life was generally on the order of
weeks, not minutes (29), making this hypothesis relatively un-
likely.
Biodistribution of the conjugate was also consistent with
previous data on IT-101 where the highest tissue concentration
at 24 h after administration was observed in tumor, followed by
the liver (19). High liver concentrations are most likely a
reflection of the accessibility of the liver interstitial space to the
nanoparticles through fenestrae with a size of 100 nm. However,
the lack of accumulation in the liver together with the low
volume of distribution and long terminal half-life indicates that
the IT-101 nanoparticles can successfully avoid significant up-
take by the reticulo-endothelial system and clearance by the
liver.
Tumor permeability of macromolecules, and therefore their
extravasation, is expected to decrease with increasing particle
size. This is due to the size of the large, intercellular openings
between endothelial cells in tumor vasculature that is not present
in normal, continuous endothelium (30). The pore cut-off size
for these openings has been shown to be between 200 nm and 1.2
m (9), varying by tumor type. The determined apparent
permeability for IT-101 was significantly smaller than the per-
meability of a 70-kDa dextran polymer but larger than that of a
2-MDa dextran. Additionally, Dreher et al. (11) found that for
a 70-kDa dextran, the tumor interstitial concentration reaches a
maximum at 15 min after injection (the maximum concentra-
tion was not experimentally determined for the 2 MDa dextran).
In contrast, interstitial concentrations of IT-101 continued to
increase up to 4 h after injection. The dynamics of IT-101 tumor
accumulation therefore indicate that the majority of the nano-
particles stay intact in circulation and do not disassemble into
individual 67-kDa polymer strands to a significant degree.
Although IT-101 exhibited a low permeability, this was clearly
compensated by a long plasma half-life, leading to a high tumor
accumulation. These data demonstrate the EPR effect, with
tumor concentration increasing gradually up to 24 h, reaching
11% ID/cm3, the highest concentration of any tissue.
The observation that tumor concentrations continued to
increase above the plasma concentration indicates significant
retention of nanoparticles. Several mechanisms have been pro-
posed for nanoparticle retention in tumors: Moore et al. found
that dextran-coated iron oxide nanoparticles accumulated in the
interstitial f luid, extracellular space, and were taken up by tumor
vascular endothelial cells, tumor-associated macrophages
(TAM), and tumor cells in a mouse glioma model (31). Uptake
by tumor endothelial cells was mostly observed in areas of
neovascularization whereas intracellular concentrations were
highest in tumor cells. Kirpotin et al. (14) showed that long
circulating liposomes accumulated predominantly in tumor
stroma, either in the extracellular space or in TAM in a breast
cancer tumor model. A Her2-targeted version of the same
liposomes achieved the same over all tumor concentration but
more internalization by cancer cells through endocytosis was
observed. CDP conjugates have been shown to be avidly taken
up by cancer cells (18). This result may be a function of the
unique surface characteristics of CDP nanoparticles, which
contain hydrophobic pockets within the cyclodextrin molecules
that have been shown to interact with lipid rafts of cell mem-
branes (16). Although the PET data are not able to distinguish
the individual contributions of each of these mechanisms to
tumor retention of IT-101, it is important to note that a
combination of any of these could contribute to the superior
antitumor efficacy seen in preclinical models (18, 20, 21). For
Fig. 3. Confocal immunofluorescence microscopy of Neuro2A tumor section. (Left) Emission at 440 nm (blue, CPT). (Center) Emission at 507 nm (green,
Au-PEG-AD). (Right) Merged image of Left and Center with brightfield image. Scale bar, 20 microns.
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example, uptake by endothelial cells in an area of neovascular-
ization could have an anti-angiogenic effect, starving the tumor
of new blood supply. Entrapment in the perivascular extracel-
lular space could lead to a continuous release of drug from the
polymer through hydrolytic and enzymatic cleavage, and subse-
quent transport of free drug to tumor cells by diffusion along a
concentration gradient. Uptake by cancer cells could lead to
intracellular release of drugs, leading to higher intracellular
tumor concentrations than could be achieved otherwise.
To ascertain the localization of IT-101 within the tumors of the
mice, Neuro2A tumors were collected 24 h after injection of
IT-101. As shown by the confocal immunofluorescence data of
Fig. 3, IT-101 is found internalized within tumor cells (Fig. 3 is
representative of numerous sections obtained). Because of the
significant colocalization of CPT and the Au-PEG-AD that
binds to cyclodextrins, it is clear that IT-101 is within the tumor
cells and not just released CPT. This localization suggests that
the sink for IT-101 within the tumor is the uptake of the
nanoparticles by the tumor cells. Tumor cell uptake of IT-101
could be the reason why the tumor amounts of both the IT-101
nanoparticles and CPT remain relatively constant for several
days after an i.v. injection as opposed to the rapid decline (over
several orders of magnitude in 24 h) of irinotecan in the same
animal model (21).
In summary, this study highlights the behavior of long-
circulating nanoparticles that are able to accumulate in tumor
tissue through the EPR effect and result in a selective accumu-
lation in tumor tissue compared with other tissues. Once accu-
mulated in tumor tissue, the nanoparticles are able to enter
tumor cells. These combined properties are advantageous for
delivery of drugs that require intracellular localization for
efficacy. Specific examples of importance would be the delivery
of chemotherapeutic agents to tumors resistant to therapy
mediated by surface protein pumps and the delivery of nucleic
acids.
Materials and Methods
General. All of the anhydrous solvents, HPLC grade solvents, and other com-
mon organic solvents were purchased from commercial suppliers and used
without further purification. CPT was purchased from Boehringer Ingelheim.
Linear copolymer of cyclodextrin and polyethylene glycol (CDP) and the
glycine derivative of CPT (TFA Glycinate CPT) were synthesized as previously
described (32). Molecular weight distributions of the polymer samples were
analyzed on a Wyatt WinGPC Unity system, coupled with double gel perme-
ation columns (PL-aquagel-OH-40, 8m, 300 7.5mm, Polymer Laboratories)
on a HP 1100 HPLC system (Agilent). Particle size measurement by dynamic
light scattering and zeta potential determinations were performed on a
ZetaPALS instrument (Brookhaven Instruments).
Synthesis of CDP-CPT3-SSPyr1. CDP (2.0 g, 0.41 mmol) was dissolved in dry
N,N-dimethylformamide (20 mL). The mixture was stirred for 20 min. TFA
Glycinate CPT (350 mg, 0.68 mmol), S-(2-Pyridyldithio) cysteamine hydrochlo-
ride (51 mg, 0.23 mmol), N,N-Diisopropylethylamine (0.16 mL, 0.91 mmol),
N-(3-Dimethylaminopropyl)-N-ethylcarbodiimide hydrochloride (240mg, 1.2
mmol), and N-Hydroxysuccinimide (100 mg, 0.91 mmol) were added to the
polymer solution and stirred for 4 h. The polymer was precipitated with
acetone (100 mL). The precipitate was dissolved in pH 3 water (100 mL) that
was prepared by acidification with HCl. The solution was dialyzed by using a
25,000MWCOmembrane (Spectra/Por 7) for 24 h at pH 3water. It was filtered
through 0.2-m filters (Nalge) and lyophilized to yield yellow solid (1.1 g,
55%).
Synthesis of CDP-CPT3-SH1. To a PBS (1x, pH 7.4) solution of CDP-CPT3-SSPyr1
(200 mg, 0.036 mmol), DTT (28 mg, 0.18 mmol) was added. The reaction
mixture was stirred for 4 h. It was then dialyzed by using a 25,000 MWCO
membrane (Spectra/Por 7) for 24 h against a degassed aqueous solution of
EDTA (EDTA1mM,2 L). Afterfiltration througha0.2-mfiltermembrane, the
solution was lyophilized to produce a light-yellow solid (160 mg, 80%).
Synthesis of CDP-CPT3-DOTA1. CDP-CPT3-SH1 (100 mg, 0.018 mmol) was dis-
solved in dry N,N-dimethylformamide (2 mL). The mixture was stirred for 20
min. 1,4,7,10-Tetraazacyclododecane-1,4,7-Tris-acetic acid-10-maleimido-
ethylacetamide (18 mg, 0.022 mmol) was added to the polymer solution and
stirred for 15 h. The polymer was precipitated with acetone (10 mL). The
precipitate was dissolved in pH 3 water (10 mL) that was prepared by acidifi-
cation with HCl. The solution was dialyzed by using a 25,000 MWCO mem-
brane (Spectra/Por 7) for 24 h at pH 3 water. It was filtered through 0.2-m
filters (Nalge) and lyophilized to yield yellow solid (68 mg, 68%). Loading of
CPT was determined to be a total of 4.9%with 0.1% free CPT per total CPT by
HPLC as previously described (32).
Determination of Cu Loading. CDP-CPT3-DOTA1 (20 mg, 0.0036 mmol) was
dissolved in0.1MammoniumacetateatpH5.5 (2mL). Copper (II) chloride (240
g, 1.7 mol) was added to the polymer solution and stirred at 60 °C for 3 h.
Bufferwas exchanged tophosphate buffer at pH7.4 by using Pierce Zeba 5mL
Desalt spin columns according to the manufacturer’s procedure, as follows:
Phosphate buffer (2.5 mL) was added to the column and centrifuged at
1,000  g for 2 min to remove buffer. This buffer-washing procedure was
repeated 3more times. Copper polymer conjugate solution (2mL)was loaded
to the column and centrifuged at 1,000  g for 2 min to obtain the sample.
Samples were analyzed for copper content by inductively coupled plasma
mass spectrometry (Galbraith Laboratories).
64Cu Labeling.All liquidswere pretreatedwith Chelex-100 (Bio-Rad) to remove
trace metal contaminants. 64Cu chloride was purchased from MDS Nordion
and the labeling procedure was performed similar the Cu loading described
above, except that the incubation was only for 1 h. The labeling yield was
determined by measuring the radioactivity in the filter, the filtrate, and the
retentate, respectively. The 64Cu-radiolabeled nanoparticles were then resus-
pended in saline for in vivo injections.
Animals and Tumor Formation for PET Studies. Nonobese diabetic (NOD)/SCID
mice were purchased from Jackson Laboratory. All animal protocols were
performed in accordance to theGuide for Care andUse of LaboratoryAnimals
and were approved by the University of California at Los Angeles Animal
Research Committee. Neuro2A mouse neuroblastoma cells (ATCC) were cul-
tured in DMEM supplemented with 10% FBS, 2 mg/mL glucose, 100 units/mL
penicillin, and 100 units/mL streptomycin. Cells were harvested with trypsin,
resuspended in PBS andMatrigel (BDBiosciences), and 1 to 2million cellswere
injected s.c. into the right flank of NOD/SCID mice. Tumors were allowed to
grow to a size of 0.5 cm3 before injection and imaging.
MicroPET CT Imaging. MicroPET/CT imaging was performed on a microPET
Focus 220 PET scanner (Siemens) and a MicroCat II CT scanner (Siemens) as
previously described (13). Briefly, anesthetized animals were placed in a
heated isolation/imaging chamber, positioned on the scanner bed, 64Cu-
labeled nanoparticles (100–300 Ci, 1 Ci 37 GBq) were injected via tail vein,
and a dynamic PET scan was acquired for 1 h with an image resolution of 1.7
mm. Immediately after the microPET scan, mice underwent a microCT scan
thatwas used for anatomical localization of the PET signal. StaticmicroPET/CT
scans were acquired at 4 h and 24 h after injection. Tracer concentration in
various tissues was determined by using the AMIDE software (33). Activity
concentrations are expressed as percent of decay-corrected injected activity
per cm3 of tissue (approximately %ID/cm3), normalized to an elliptic cylinder
region of interest drawn over the entire mouse. Plasma concentrations were
calculated frommeasured whole-blood concentrations by using a hematocrit
of 33%.
Animals and Tumor Formation for Tumor Collections. Immunodeficient
(NOD.CB17-Prkdcscid/J) mice were purchased from The Jackson Laboratory.
All animal manipulations, performed with sterile techniques, complied with
the National Institutes of Health Guidelines for Animal Care and were per-
formed as approved by the Caltech Institutional Animal Care and Use Com-
mittee. Neuro2A cells were cultured in complete growth medium (DMEM
supplemented with 10% FBS (FBS), 100 units per mL penicillin, and 100 units
permL streptomycin). In the right hindflank,mice received a s.c. implantation
of Neuro2A cells (at 1 million cells per mouse per 0.1 mL of DMEM). Before
injection, tumors reached 100–200 mm3 in size, as determined by caliper
measurements. Mice received i.v. administration of IT-101 (10 mg of polymer
per kg of animal; formulated in 0.1 mL of D5W) via the tail vein. As a control,
mice received i.v. injections of 0.1 mL of D5W. Animal euthanization by CO2
took place 24 h after injection, immediately followed by tumor extraction.
Confocal Immunofluorescence Microscopy. After immersion fixation in 4%
paraformaldehyde for 3 days, 2-cm3 tumor tissue blocks passed through an
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increasing sucrose gradient up to 30% sucrose, and were later embedded in
9% gelatin. The gradual freezing of gelatin tissue blocks to 80 °C allowed
the generation of 10 m-thick cryosections. After brief rinsing with PBS to
remove any surface gelatin, as well as fixation with acetone at 20 °C to
permeabilize the cell membrane, tissue sections received the staining of
PEGylated, AD-modified gold nanoparticles (Au-PEG-AD) in the dark for 2 h.
Rinsingwith PBS removed any nonspecifically bound gold particles before the
mounting of Au-PEG-AD-stained tumor sections with Mowiol 4–88 and glyc-
erol. A Zeiss LSM 510 confocal scanning microscope was used to collect the
images (CPT-excitation: 370 nm, emission: 440 nm; Au-PEG-AD-excitation: 488
nm, emission: 507 nm).
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